ENDRA Reports Favourable Data From Taeus Liver Device Study in MASLD

Why It Matters

A reliable, affordable liver‑fat assessment tool enables more frequent patient monitoring and supports drug development, addressing a critical gap in MASLD management.

Key Takeaways

• ICC of 0.89 demonstrates strong reproducibility.
• SEM of 3.3% rivals MRI-PDFF accuracy.
• Study involved 14 participants, 56 measurements.
• Point‑of‑care device reduces cost versus MRI.
• Supports regulatory validation for clinical decision‑making.

Pulse Analysis

Metabolic dysfunction‑associated steatotic liver disease (MASLD) now affects over two billion people worldwide, creating an urgent need for scalable diagnostic solutions. Traditional MRI‑PDFF, while accurate, remains prohibitively expensive and logistically challenging for routine use. Point‑of‑care technologies like ENDRA's Taeus Liver device aim to bridge this gap by delivering quantitative liver‑fat measurements directly in clinical settings, potentially democratizing access to high‑quality monitoring across diverse healthcare environments.

The recent validation study underscores Taeus's technical robustness. With an intraclass correlation coefficient of 0.89 and a standard error of measurement at just 3.3%, the device demonstrates reproducibility comparable to MRI benchmarks. By collecting 56 measurements across 14 participants, the study isolates device variability from patient differences, a critical step for regulatory acceptance. This consistency also starkly contrasts with conventional ultrasound, which suffers from operator‑dependent variability and subjective interpretation.

For clinicians and pharmaceutical sponsors, the implications are significant. Reliable, low‑cost liver‑fat quantification enables more frequent assessments, improving disease tracking and therapeutic response evaluation. In drug trials, standardized measurements can reduce endpoint variability, accelerating development timelines. As healthcare systems seek cost‑effective diagnostics, Taeus's validated performance positions it to capture market share, prompting broader adoption and potentially reshaping MASLD management protocols.